Business, energy, technology, markets and global industry news from Business News Today

gram-negative infections

PharmaDeviceNews gram-negative infections
Representative image: A clinical research laboratory setting illustrates Meiji Seika Pharma’s nacubactam Phase III progress, as the novel β-lactamase inhibitor advances the fight against complicated urinary tract infections, acute pyelonephritis and antimicrobial resistance.
Pharma & Biotech

Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain

Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.

Read More
Pharma & Biotech

From ARPA-H to Basilea: What Phare Bio’s new deal reveals about biotech partnerships

Phare Bio and Basilea partner to develop an AI-designed antibiotic for deadly gram-negative infections. Explore what this deal could mean for the future of antimicrobial R&D.

Read More